Summer Comfort Application

Deadline: 5/31/2024 (or as funds permit)



Applicant's Name:				
Address (Street):				
City:		_ State:	Zip Code:	
Phone:				
Email:				
Briefly describe how you wo	ould use the air conditioner and h	now it would im	prove your quality of lif	fe:
Employed: Occupation	:			Retired: □
Type of MS				
Date Diagnosed:	Where/By:			
Provide evidence (required)	of MS diagnosis (chart note, doc	tor's note or co	opy of MS medication b	oox).
	Financial Informati	ion (require	ed)	
Please mark "0" to those the	at do not apply:			
Income/Source		<u>Expenses</u>		
SSI/SSDI	Re	ent/Mortgage		
Work		Food		
Family/ SNAP		Jtilities/Other		
Other Source		Vehicle Exp.		
Total \$		Total \$		
Do you have any asset, liabi	ility or other financial information	you would like	to include that is not c	outlined above?
this application and hereby		diagnosis. I und R 97015, or em	derstand this application	on is to be sent soregon.org or
Signature:		Da	ate:	

Application Instructions

<u>Step 1</u>: You must provide documentation of your MS diagnosis. This can be a medical chart note that includes your name and diagnosis, a doctor's note or a copy of the card board cover of one of the following medications:

Injectable Medications:

Avonex® (interferon beta-1a)

Betaseron® (interferon beta-1b)

Copaxone® (glatiramer acetate)

Extavia® (interferon beta-1b)

Glatiramer Acetate Injection (glatiramer acetate -generic equivalent of Copaxone 20 mg and 40 mg doses)

Plegridy® (peginterferon beta-1a)

Glatopa® (glatiramer acetate-generic equivalent of Copaxone) 20 mg and 40 mg doses)

Rebif® (interferon beta-1a)

Kesimpta® (ofatumumab)

Oral Medications:

Aubagio® (teriflunomide)

Bafiertam™ (monomethyl fumarate)

Dimethyl Fumarate (dimethyl fumarate-generic equivalent of Tecfidera)

Gilenya® (fingolimod)

Mavenclad® (cladribine)

Mayzent® (siponimod)

Ponvory[™] (ponesimod)

Vumerity® (diroximel fumarate)

Zeposia® (ozanimod)

Infused Medications:

Lemtrada® (alemtuzumab)

Novantrone® (mitoxantrone)

Ocrevus® (ocrelizumab)

Tysabri® (natalizumab)

Step 2: Submit your completed application along with proof of diagnosis to 10117 SE Sunnyside Rd., #709, Clackamas, OR 97015, email to programs@msoregon.org or fax 503 563-5995. **May 31, 2024** is the application deadline. For questions call 503 297-9544.